Sermorelin: what the Geref studies establish

Separate the products

Sermorelin is the amidated GHRH fragment containing amino acids 1 through 29. Geref had separate historical approvals for pituitary growth-hormone testing and for children with idiopathic growth-hormone deficiency and growth failure. Those indications do not establish an adult anti-aging use.

Geref is discontinued. FDA withdrew both application approvals effective June 18, 2009. In 2013, FDA determined that the products had not left sale for safety or effectiveness reasons. That finding does not approve today's compounded sermorelin.

Read the actual trial

A 2004 randomized, double-blind trial enrolled 31 men with HIV-associated lipodystrophy. It compared subcutaneous Geref given twice daily for 12 weeks with placebo. This describes the study, not a schedule for personal use.

IGF-1, the primary outcome, increased. Lean body mass also increased, but the between-group visceral-fat comparison did not reach statistical significance. This small, short trial cannot establish healthy-aging benefits or long-term safety. It also cannot validate a different formulation, route, blend, or schedule.

A plan needs a product identity

There is no current FDA-approved sermorelin product label to use as a personal treatment plan. The cited adult trial does not establish a validated longevity regimen. Compounded drugs do not receive FDA premarket approval.

If your clinician has supplied a plan, record sermorelin acetate by its full name, the dispensing pharmacy, formulation, concentration, prescribed amount and unit, route, timing, and intended duration. Keep the clinical reason, follow-up measurements, review date, and instructions for symptoms or stopping alongside the record. Those details must come from your clinician and pharmacist. A historical brand name alone cannot fill them in.